Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267


Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011.

Na R, Jiang H, Kim ST, Wu Y, Tong S, Zhang L, Xu J, Sun Y, Ding Q.

PLoS One. 2012;7(11):e49914. doi: 10.1371/journal.pone.0049914.


Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.

Na R, Wu Y, Xu J, Jiang H, Ding Q.

PLoS One. 2013;8(6):e67585. doi: 10.1371/journal.pone.0067585.


Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052.


The influence of prostate volume on cancer detection in the Chinese population.

Wu YS, Na R, Xu JF, Bai PD, Jiang HW, Ding Q.

Asian J Androl. 2014 May-Jun;16(3):482-6. doi: 10.4103/1008-682X.125905.


Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.

Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y, Ding Q, Xu J.

Prostate. 2014 Nov;74(15):1569-75. doi: 10.1002/pros.22876.


A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x.


Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, Tscholl R.

Urology. 2000 Apr;55(4):481-5.


Percent free PSA as an additional measure in a prostate cancer screen.

Miele ME.

Clin Lab Sci. 2001 Spring;14(2):102-7.


Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x.


Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.


Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H.

Prostate. 2001 Oct 1;49(2):101-9.


Clinical usefulness of free PSA in early detection of prostate cancer.

Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H; Early Detection Project Group of the German Society of Urology..

Onkologie. 2001 Feb;24(1):33-7.


Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.

Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, Higashihara E.

Int J Urol. 2003 Apr;10(4):201-6.


Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A.

Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784.


Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011.


Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.

Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.

Eur Urol. 2008 Apr;53(4):750-7.


The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen.

Dalva I, Akan H, Yildiz O, Telli C, Bingol N.

Int Urol Nephrol. 1999;31(5):675-80.


Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.

Toubert ME, Guillet J, Chiron M, Meria P, Role C, Schlageter MH, Francois H, Borschneck C, Nivelon F, Desgrandchamps F, Rastel D, Cussenot O, Teillac P, Le Duc A, Najean Y.

Eur J Cancer. 1996 Nov;32A(12):2088-93.


Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies.

Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, Sinha P, Loening SA, Jung K.

Clin Chem. 2002 Aug;48(8):1279-87.

Items per page

Supplemental Content

Support Center